Extensive expression of B7-H3 has been reported in a variety of cancer types, and correlation with poor prognosis is also widely established, with the notion that the expression of B7-H3 is heterogenous and that B7-H3 in B7-H3 low-expressing or metastatic cancer needs additional investigation. Here, CD276 is linked to cancer.